Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Results from the randomized, phase 3 STARGLO trial of patients with transplant-ineligible relapsed or refractory DLBCL showed significantly improved overall survival (OS) with glofitamab plus gemcitabine/oxaliplatin compared with rituximab plus gemcitabine/oxaliplatin. After a median follow-up of 11.3 months, median OS was not estimable versus 9.0 months, respectively (HR 0.59; 95% CI, 0.40–0.89; P = .011). A consistent improvement in OS was also seen in an updated analysis with a median follow-up of 20.7 months (median 25.5 months versus 12.9 months, respectively; HR 0.62; 95% CI, 0.43–0.88).